Abbott India

Abbott India makes ‘Digene’ the number one antacid in India. Abbott bought Piramal Healthcare’s domestic formulation business, including the Baddi factory, for over Rs 17,000 crore in March 2010, in one of the biggest acquisitions in India’s pharmaceuticals industry. It  included transfer of rights over 350 brands and trademarks. Apart from its new plant in Gujarat, it has another factory at Goa. It has two R$D facilities – one was acquired from Piramal and other one is in Bangalore.

The company posted a stable performance for Q3FY16 – no great shakes. On a 16% (YoY) rise in net sales at Rs.650 crore, the company posted a net profit of Rs.70 crore, up 9%. EBITDA for the quarter was at Rs.102 crore, up 19% and margins were stable at 15.69% v/s 15.30%.

The company’s equity stands at Rs.21.25 and reserves at Rs.916 crore. Debt free, its 9MFY16 net profit of Rs.201 crore is already 88% of FY15 entire year’s profit. With one more quarter to go, clearly it will end current fiscal on a high note.